Overview

SPI is focused on developing therapeutics to address patients with significant unmet medical needs in the space of sensorineural otologic diseases.

For additional details of SPI’s clinical trials, please follow the link to Clinicaltrials.gov

Our Product Pipeline

Indication
Therapeutic Candidate

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

Acute NIHL
Mild to Moderate

SPI-1005

(Phase 2)

60%

Click for Status

SPI-1005 reduced the incidence and severity of NIHL,

published in The Lancet – July 2017

For more information regarding ongoing or upcoming studies see Clinicaltrials.gov

Meniere’s Disease
SPI-1005

(Phase 2)

60%

Click for Status

Phase 1b Meniere’s Disease clinical trial completed,

see presentation at 2018 ARO

For more information regarding ongoing or upcoming studies see Clinicaltrials.gov

Chemotherapy-Induced Ototoxicity
SPI-3005

(Phase 1)

50%

Click for Status

For more information regarding ongoing or upcoming studies see Clinicaltrials.gov

Aminoglycoside-Induced Ototoxicity
SPI-3005

(Phase 1)

50%

Click for Status

Phase 1b STOP Ototoxicity study completed,

see presentation at 2018 NACFC

For more information regarding ongoing or upcoming studies see Clinicaltrials.gov

Severe to Profoundly
Impaired

SPI-5557

(Phase 1)

20%

Click for Status

Anticipate IND filing in Q4 2018

Our Product Pipeline